What human trials say about scalp microneedling, needle depth and frequency, and why a positive study does not establish a universal home protocol.
Scalp microneedling has some human evidence as an addition to minoxidil for androgenetic alopecia. That does not establish one best needle depth or frequency, and it does not make a clinic study a validated home protocol. Deeper needles and more frequent sessions should not be assumed to produce more regrowth.
The most useful distinction is between evidence that a treatment combination helped and evidence identifying which part of its protocol caused the benefit. The studies below answer different questions. Sources were checked on September 18, 2026.
Dhurat and colleagues enrolled 100 men aged 20–35 with mild to moderate androgenetic alopecia. Both groups used 5% minoxidil; one also received weekly microneedling with a 1.5 mm roller for 12 weeks. Ninety-four completed the study. The combination group improved more on the reported hair-count and photographic measures. Read the original study
The procedure endpoint was mild redness, not a requirement to cause bleeding. Participants withheld minoxidil on the procedure day and resumed it 24 hours later. These describe that trial, not a recommendation for self-treatment.
This was a short pilot with a blinded evaluator, no sham-needling group, and six losses to follow-up in the minoxidil-only group. It did not compare depths or frequencies. Its result therefore cannot establish that 1.5 mm is optimal, that weekly sessions are safest, or that microneedling works equally well without minoxidil.
Faghihi and colleagues studied 60 adults over 12 weeks, comparing minoxidil alone with minoxidil plus microneedling at 0.6 mm or 1.2 mm. The published abstract reports greater hair-count and hair-thickness improvement for the 0.6 mm group than for minoxidil alone. It describes that depth as tending to be more beneficial than 1.2 mm. Original trial abstract, published online in 2020 and in a 2021 issue
That finding challenges the assumption that deeper always works better. It does not establish an optimum for every device, scalp region or patient. The full subscription report was unavailable for this review; the abstract alone does not support detailed claims about regional technique or long-term safety.
A trial published online in May 2026 randomized 245 women with mild to moderate androgenetic alopecia to 2% minoxidil alone or with microneedling every two or four weeks. It used a 36-needle cartridge at 0.50–0.55 mm. Among the 234 participants who completed 24 weeks, the published abstract reports no significant between-group difference in the primary nonvellus hair-count outcome or secondary outcomes. Liu and colleagues, 2026
This single-center, open-label trial did not find an added benefit for those regimens. It does not prove that every microneedling approach is ineffective, nor can its results be assumed identical in men using 5% minoxidil. It does show why positive older studies should not become a universal recommendation. The full report could not be retrieved; this account is limited to the original published abstract.
A chart assigning one needle length to temples and another to the crown looks precise. To validate it, researchers would need to compare those regional approaches while keeping other treatment factors sufficiently similar. The studies above do not do that.
Likewise, comparing a weekly protocol in one study with a different interval in another does not isolate frequency. Differences in participants, devices, background medication and outcome measurement can also explain different results. These are limits of the comparison, not proof that frequency is irrelevant.
When reading a protocol claim, ask:
Do not translate a target-area hair-count change into a promised percentage increase across your whole scalp.
As checked for this update, the FDA states that it has not cleared microneedling devices for hair loss or for use with another product. Clearance for certain skin indications does not cover scalp regrowth or drug delivery. The FDA recommends a provider with appropriate microneedling training. FDA consumer guidance
Professional assessment is especially relevant when the diagnosis is uncertain or the scalp is already irritated. A procedure can have a plausible biological rationale without having a validated schedule for your situation.
Use it to ask a dermatologist whether adding a procedure is justified, what evidence supports their specific plan, and how the added benefit will be assessed. Our microneedling plan checklist turns those questions into an appointment record.
If you already have pain, persistent irritation or possible infection after needling, use the scalp warning-sign guide and seek appropriate care. Choosing a different needle setting is not a substitute for assessing an injury.
Powered by BTST